CARsgen Launches First-in-Class Anti-Claudin18.2 CAR-T Clinical Trial

61

SHANGHAI, Aug. 10, 2017 /PRNewswire/ — CARsgen Therapeutics (CARsgen), a global leader in developing chimeric antigen receptor T-cell (CAR-T cell) therapies for solid tumors, today announced its first-in-class anti-Claudin18.2-CAR-T cell therapy for gastric and pancreatic cancers has… http://www.prnewswire.com/news-releases/carsgen-launches-first-in-class-anti-claudin182-car-t-clinical-trial-300502521.html